--- title: "Yarrow Bioscience (YARW) news: Nasdaq notice and merger" url: "https://aibio.space/companies/yarrow-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "YARW Nasdaq notice and merger news: VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock. Yarrow Bioscience, Inc." --- YARW Yarrow Bioscience, Inc. NASDAQ · United States # Yarrow Bioscience (YARW) news YARW Nasdaq notice and merger news Listings · 2026-03-11 ## [VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-bid-price/) Nasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences. ## Latest Yarrow Bioscience news 1. 2025-09-12 Listings [VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq minimum bid price notice](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-minimum-bid-price/) Nasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now. 2. 2025-09-12 Listings [VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-notice-sub-1-00/) VYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share. ## Yarrow Bioscience at a glance - **Ticker**: YARW - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $22.9 million ### Related companies - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [Moleculin Biotech](https://aibio.space/companies/moleculin-biotech/) NASDAQ: MBRX - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD - [Vogenx](https://aibio.space/companies/vogenx/) NASDAQ: VOGX - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) NASDAQ: ATRA - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN ### Also on NASDAQ - [City Therapeutics](https://aibio.space/companies/city-therapeutics/) CTY - [QuidelOrtho](https://aibio.space/companies/quidelortho/) QDEL - [Pulsenmore](https://aibio.space/companies/pulsenmore/) PLSM - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) BCAX - [Ascendis Pharma](https://aibio.space/companies/ascendis-pharma/) ASND - [Pulmatrix](https://aibio.space/companies/pulmatrix/) PULM ## Yarrow Bioscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$19.2 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | [$30.9 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | | Net income (loss) | [-$26.5 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | [-$39.8 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | | Cash from operations | [-$33.1 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | [-$34.0 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | | Cash and equivalents | [$24.0 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000010/) | [$19.9 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | | Short-term investments | [$5.0 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000005/) | [$41.6 million](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.9 million, plus short-term investments of $0, $22.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Yarrow Bioscience Has Yarrow Bioscience received a Nasdaq deficiency notice? Our latest story on this, dated Sep 12, 2025: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-notice-sub-1-00/). Is Yarrow Bioscience involved in a merger or acquisition? Our latest story on this, dated Mar 11, 2026: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-bid-price/). What is the ticker symbol of Yarrow Bioscience? Yarrow Bioscience, Inc. trades under the ticker YARW on NASDAQ. Where is Yarrow Bioscience listed? Yarrow Bioscience, Inc. is listed on NASDAQ. What is the SEC CIK of Yarrow Bioscience? The SEC Central Index Key (CIK) for Yarrow Bioscience, Inc. is 1566044. Its filings are on SEC EDGAR. How many shares does Yarrow Bioscience have outstanding? 2,669,746 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Yarrow Bioscience listed under? Our directory records Yarrow Bioscience, Inc. under United States. What does Yarrow Bioscience do? Our directory classifies Yarrow Bioscience, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Yarrow Bioscience? The ISIN recorded for Yarrow Bioscience, Inc. is US92941V4077. Does aibio.space cover Yarrow Bioscience? aibio.space lists Yarrow Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Yarrow Bioscience incorporated? SEC records list its state or country of incorporation as DE. Is Yarrow Bioscience profitable? Yarrow Bioscience, Inc. reported a net loss of $26.5 million for the fiscal year ended Dec 31, 2025, and used $33.1 million of cash in operations, per its annual report to the SEC. How much does Yarrow Bioscience spend on research and development? $19.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Yarrow Bioscience have? $22.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Yarrow Bioscience (YARW) stock news? Our latest story on Yarrow Bioscience, dated Mar 11, 2026: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026". Nasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences. [Source](https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-bid-price/). ## Investor discussion: Yarrow Bioscience Members talk about Yarrow Bioscience (YARW). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Yarrow Bioscience, newest first. Each line links the filing it comes from. 1. 2026-09-11 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465926107102/tm2624918-1_424b5.htm) 2. 2026-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000010/vyne-20260630.htm) 3. 2026-07-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465926085235/tm2620874d1_ex99-1.htm) 4. 2026-07-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/tm2620687d2_8k.htm) 5. 2026-07-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465926082433/tm2620182d1_ex99-1.htm) 6. 2026-03-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/tm268461d1_8k.htm) 7. 2026-02-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm) 8. 2025-12-17 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/tm2533624d1_ex99-1.htm) 9. 2025-09-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1566044/000110465925089531/tm2525917d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:YARW on TradingView](https://www.tradingview.com/symbols/NASDAQ-YARW/). ## SEC filings and registration - **SEC name**: Yarrow Bioscience, Inc. - **CIK**: 1566044 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: YARW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513 - **Phone**: (203) 433-7577 - **Shares outstanding**: 2,669,746 as of 2026-08-10 (10-Q filed 2026-08-13) - **Former names**: VYNE Therapeutics Inc.; Menlo Therapeutics Inc.; Menlo Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1566044/000110465926107485/tm2624918d3_8k.htm) filed 2026-09-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1566044/000110465926107112/tm2624918-2_424b5.htm) filed 2026-09-11 - [424B5](https://www.sec.gov/Archives/edgar/data/1566044/000110465926107102/tm2624918-1_424b5.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/tm2624937d1_8k.htm) filed 2026-09-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000010/vyne-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/tm2621655d2_8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/tm2620687d3_8k.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1566044/000110465926085235/tm2620874d1_8k.htm) filed 2026-07-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001566044), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Yarrow Bioscience, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker YARW, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Yarrow Bioscience, Inc. - **Ticker**: YARW - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92941V4077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-YARW/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/yarrow-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Yarrow Bioscience (YARW) news: Nasdaq notice and merger", 2026-10-31, https://aibio.space/companies/yarrow-bioscience/